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Abstract
Metabolic syndrome can induce chronic kidney disease in humans. Genetically engineered mice on a C57BL/6
background are highly used for mechanistic studies. Although it has been shown that metabolic syndrome induces
cardiovascular lesions in C57BL/6 mice, in depth renal phenotyping has never been performed. Therefore in this
study we characterized renal function and injury in C57BL/6 mice with long-term metabolic syndrome induced by a
high fat and fructose diet (HFFD). C57BL/6 mice received an 8 months HFFD diet enriched with fat (45% energy from
fat) and drinking water enriched with fructose (30%). Body weight, food/water consumption, energy intake, fat/lean
mass ratio, plasma glucose, HDL, LDL, triglycerides and cholesterol levels were monitored. At 3, 6 and 8 months,
renal function was determined by inulin clearance and measure of albuminuria. At sacrifice, kidneys and liver were
collected. Metabolic syndrome in C57BL/6 mice fed a HFFD was observed as early 4 weeks with development of
type 2 diabetes at 8 weeks after initiation of diet. However, detailed analysis of kidney structure and function showed
only minimal renal injury after 8 months of HFFD. HFFD induced moderate glomerular hyperfiltration (436,4 µL/min
vs 289,8 µL/min; p-value=0.0418) together with a 2-fold increase in albuminuria only after 8 months of HFFD. This
was accompanied by a 2-fold increase in renal inflammation (p-value=0.0217) but without renal fibrosis or mesangial
matrix expansion. In addition, electron microscopy did not show alterations in glomeruli such as basal membrane
thickening and foot process effacement. Finally, comparison of the urinary peptidome of these mice with the urinary
peptidome from humans with diabetic nephropathy also suggested absence of diabetic nephropathy in this model.
This study provides evidence that the HFFD C57BL/6 model is not the optimal model to study the effects of metabolic
syndrome on the development of diabetic kidney disease.
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Introduction
The food industry has evolved, providing a supply of
increasingly rich diet in terms of fatty acids [1] and fructose [2].
This shift is not without consequences on general health
including increase risk of developing obesity, insulin resistance,
hepatic steatosis and diabetes [3-10]. Metabolic syndrome is a
complex pattern of disorders referring to the joint occurrence of
several risk factors including obesity, mixed dyslipidemia and
high glucose blood levels [11]. Metabolic syndrome is very
common in developed countries and its prevalence is expected
to further increase in the near future [12], in parallel with the
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rapidly increasing prevalence of obesity [13,14]. Metabolic
syndrome and its risk factors potentially play a role in the
development of chronic kidney diseases (CKD). Indeed, it has
been shown that metabolic syndrome is associated with a
higher prevalence of microalbuminuria [15-20] and an higher
risk of development of CKD [21] and subsequent end stage
renal disease (ESRD) in type II diabetic patients [22]. However,
detailed mechanistic information on the link between metabolic
syndrome and CKD is not available.
Hence, to better understand this link, rodent models
mimicking as best as possible human metabolic syndrome-
induced CKD will be of great help. It has been shown that a 3
or 4 months diet containing respectively 60% or 45% kcal of fat
leads to mesangial matrix area expansion in renal glomeruli
and to a significant rise in urinary albumin excretion in C57BL/6
mouse [23,24]. Furthermore, the use of fructose alone
(between 20% and 40%) in mouse and rat diets has been
reported to induce renal tubulointerstitial injury [25,26]. The
drawback of these models is that they only mimic certain
aspects of metabolic syndrome but not the entire repertoire
[27]. In contrast, a combination of high fat and high
carbohydrate diet in animals leads to the development of all
typical metabolic complications present in human metabolic
syndrome such as increased body weight, increased
triglycerides and cholesterol plasma concentrations, and
abdominal fat deposition [28-31]. The latter is thus probably the
most appropriate model to study human metabolic syndrome in
animal models [27] and therefore its impact on kidney function.
Recent studies by Panchal et al. [32] submitting rats to both a
high fat and high fructose diet for 4 months showed
cardiovascular remodeling (i.e endothelial dysfunction,
inflammation and fibrosis in the heart) in the presence of
metabolic syndrome. Unfortunately, effects on the kidney were
only minimally described which did not allow concluding on the
suitability of this metabolic syndrome model to induce CKD. In
addition, the workhorse for genetically engineered mice is the
C57BL/6 strain and induction of metabolic syndrome in this
strain deficient for specific genes would be of great help to
better understand the development of CKD in metabolic
syndrome.
Figure 1.  Changes in body weight (A), energy intake (B), food intake (C), water intake (D), fat mass (E) and lean mass (F) in
control fed mice (■) and HFFD fed mice (▲).  Data are means ± SEM for 36 mice per group at 1, 2 and 3 months, 24 mice per
group at 6 months and 12 mice per group at 8 months. *P≤0.05, **P≤0.01, ***P≤0.001.
doi: 10.1371/journal.pone.0076703.g001
Kidney Lesions in Metabolic Syndrome in Mice
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Therefore in the current study we describe the in depth
characterization of kidney lesions after a long term (8 months)
high fat high fructose diet (HFFD) in the C57BL/6 mouse strain.
We observed that the kidney is particularly resistant to
metabolic syndrome in this strain since only very mild signs of
kidney damage were observed after 8 months of HFFD.
Materials and Methods
Mice and diets
Seventy-eight adult male C57BL/6 (nomenclature C57BL/
6NCrl) mice were purchased at Charles River Laboratory
(L’Arbresle, France) at the age of 5 weeks and divided in two
equal experimental groups (n=36). Mice were housed 4 per
cage and maintained on a 12h light/12h dark cycle in a
pathogen-free environment. Mice were fed with either a control
diet or a high fat fructose diet (HFFD). The control diet
(D12450B; 3,82 kcal per g; Research Diet, USA) contained
19.2% protein, 67.3% carbohydrate and 4.3% fat and was
served with regular drinking water; both ad libitum. The HFFD
(D12451; 4,73 kcal per g; Research Diet, USA) contained 24%
protein, 41% carbohydrate and 24% fat and was served with
30% fructose (F0127 powder diluted in ultrapure water; 1,2 kcal
per ml; Sigma, France) enriched drinking water; both ad
libitum. All experiments reported were conducted in
accordance with the NIH guide for the care and use of
laboratory animals and were approved by the animal care and
use committee from UMS US006/INSERM, Toulouse, France
(protocol 11/1048/12/19).
Body weight, composition and energy intake
Mice were weighed weekly. The body composition (fat and
lean mass) of awake mice was analyzed by nuclear magnetic
resonance using an EchoMRI-3in1 apparatus for Live Animals
(EchoMRI, USA) [33]. Food intake was estimated as the
difference of weight between the offered and the remnant
amount of food at 7-days intervals. The food was provided as
pressed pellets so the residual spillage was not considered
here. Beverage intake was estimated with the same process
based this time on the volume. Total energy intake, determined
from the energy content in each diet and mass consumed, was
calculated on a per-week basis.
Figure 2.  Plasma level of triglycerides (A), cholesterol (B), HDL (C), LDL (D) and glucose (E) in control fed mice (■) and
HFFD fed mice (▲).  Data are means ± SEM for 12 mice per group. *P≤0.05, **P≤0.01, ***P≤0.001.
doi: 10.1371/journal.pone.0076703.g002
Kidney Lesions in Metabolic Syndrome in Mice
PLOS ONE | www.plosone.org 3 October 2013 | Volume 8 | Issue 10 | e76703
Blood analysis
Prior to blood collection, we performed a 6 hours fasting
period. This time point was chosen to avoid a postprandial
glycemic peak and to prevent an induced catabolic state in the
mice [34,35]. All the blood samples were collected in
Microvette CB 300 Plasma/Lithium heparin (Sarstedt,
Germany) tubes from the tail vain under local anesthesia (n=12
per group). The samples were centrifuged at 3000 g for 10
minutes at 4°C. The supernatants were separated and plasma
concentrations of glucose, cholesterol, HDL, LDL and
triglycerides were measured by fluorescence on ABX Pentra
400 apparatus (Horiba medical, France). In order to bypass
multiple periods of fasting and blood collection, all the
parameters were measured from the same sample.
Renal function study
After 3, 6 and 8 months of diet, glomerular filtration rate
(GFR) was evaluated by measurement of inulin clearance in 9
mice per group as previously described [36]. Briefly mice were
anesthetized with an intraperitoneal injection of 150 mg/kg of
thiobutabarbital sodium (Inactin, Sigma) and placed on a
thermostatically controlled heating table. After a tracheotomy,
the left jugular vein was cannulated to infuse Gelofusine and a
mixture of NaCl (0.9%), thiopenthal sodium (pentothal,
0.83mg·kg-1·min-1), inulin (1.8 mg·kg-1·min-1). The rate of
infusions was 0.1 ml/h. The left femoral artery was cannulated
to monitor mean arterial blood pressure (MABP) and to obtain
blood samples. Urine was obtained in the following way: A 3
mm ventral incision was made opposite to the bladder, below
the peritoneum, allowing to expose the bladder. Then a
polyethylene catheter (internal diameter 0.58 mm; external
diameter 0.96 mm) was introduced in the bladder lumen by a 1
mm incision. The bladder was then tied around the catheter
using surgical suture. The residual urine is removed from the
bladder and a 30 min period of recovery is observed. During
GFR evaluation, a 500 µl tube is disposed at the free extremity
of the catheter to collect urine during 60 minutes. At the end of
surgery, a bolus of inulin (inulin: 100 mg/kg) was perfused, and
mice were allowed to recover for 30 min. Renal function was
evaluated for a 60-min clearance period. Inulin levels in plasma
and urine samples were determined by enzymatic
quantification of released fructose units (Enzytec D-Glucose/
Fructose kit, r-biopharm®) on a Pentra 400 analyzer (Horiba
Medical®) after a one hour 37°C incubation of the samples with
inulinase (Sigma®). The GFR is equal to the inulin clearance
(GFR = ([urinary inulin] x urine flow) / [inulin]).
Albuminuria
Mice were placed in metabolic cages in order to collect 24-h
urine. Urinary albumin excretion was determined with a mouse
antigen specific ELISA (Mouse Albumin Quantitation Kit, Bethyl
Laboratories®, USA). Creatinine measurements were
determined by an enzymatic colorimetric assay using an ID-MS
traceable calibration (Creatinine Enzymatic, Beckman Coulter)
on the Pentra 400 analyzer (Horiba Medical®). Albumin
excretions were related to urine creatinine concentrations in
order to take into account the differences in urinary flows.
Figure 3.  Marked vacuolar degeneration indicating fat accumulation in the liver of HFFD fed mice (■) compared to control
fed mice (▲).  Hematoxylin/eosin staining. Data are means ± SEM for 12 mice per group. ***P≤0.0001.
doi: 10.1371/journal.pone.0076703.g003
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Organ collection
Kidneys and liver were collected from each mouse included
in the renal function study. For brightfield microscopy, tissues
were fixed in Carnoy’s solution for 24 h. For electron
microscopy, tissues were fixed and stored with 2%
glutaraldehyde in Sorensen buffer for 1 hour.
Histological analysis and immunochemistry
Four-micrometer paraffin-embedded sections were cut.
Renal and liver sections were subjected to histological
analysis, using hematoxylin-eosin and periodic acid-Schiff
staining. For immunohistochemistry experiments, renal
sections were first dewaxed in toluene and rehydrated through
a series of graded ethanol washes before endogenous
peroxidase blockage (S2001, DakoCytomation, Trappes,
France). Specific primary antibodies were incubated (1h at
room temperature) for the detection of collagen type III (1/500;
Tebu-Bio, Le Perray-en-Yvelines, France) and F4/80 positive
cells (1/250; RM2900; Caltag Laboratories Inc., Burlingame,
CA, USA). Slides were further incubated with peroxidase-
conjugated secondary antibodies during 30 min. Immunological
complexes were visualized by the addition of the DAB
substrate during 10 min (K4010, DakoCytomation Envision
HRP system). Sections were counterstained with hematoxylin
and mounted. Negative controls for the immunohistochemical
procedures included substitution of the primary antibody with
nonimmune sera. Sections were scanned using a Nanozoomer
2.0 RS (Hamamatsu Photonics SARL, Massy, France) and
treated with the Morpho-expert image-analysis software
(version 1.00, Explora Nova, La Rochelle, France) for
morphometric analyses.
Transmission electron microscopy
Samples were fixed with 2% glutaraldehyde in Sorensen
phosphate buffer (0.1 M, pH 7.4) for 1 hour, washed with the
Sorensen phosphate buffer for 12 hours and post fixed with 1%
OsO4 in Sorensen phosphate buffer for 1 hour. Samples were
dehydrated with increasing ethanol concentration (30%, 50%,
70%, 95%) until a 100% ethanol solution was reached and then
subsequently stored for 30 min in a propylene oxide solution.
Next, samples were embedded in epoxy resin (Epon 812).
After 24 h of polymerization at 60°C, ultrathin sections (70 nm)
were mounted on 100 mesh collodion-coated copper grids and
poststained with 3% uranyl acetate in 50% ethanol and with
8.5% lead citrate before being examined on a HT7700 Hitachi
electron microscope at an accelerating voltage of 80 KV. A
series of 10 photographs were taken at x12000 magnification.
For assessment of basement membrane thickness, a grid (grid
size = 30cm by 30 cm with a 0.5 cm step) was projected on
each photograph and basement membrane thickness was
measured at points where it intersected with the grid [37]. For
assessment of foot process effacement, the number of
podocytic foot processes was manually counted and expressed
as the number of foot processes per µm of glomerular
basement membrane length [38].
Figure 4.  Glomerular hyperfiltration (A), urinary albumin to creatinine ratio (ACR) (B) and arterial blood pressure (C) in
HFFD fed mice (■) compared to control fed mice (▲).  Data are means ± SEM for 9 mice per group; *p=0.0429; **p=0.004.
doi: 10.1371/journal.pone.0076703.g004
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Urine sample preparation for CE-MS analysis
For the analysis of the urinary peptidome, urine samples
from all mice of each group were collected during 12 hours
using a metabolic cage and frozen at -80°C until CE-MS
analysis. Urine for peptidome analysis was obtained 2 days
prior to inulin based GFR measurements. Immediately before
preparation, mouse urine aliquots were thawed and 150 µl was
mixed with 150 µl of a buffer 2 M urea, 10 mM NH4OH
containing 0.02% SDS. Subsequently, samples were
ultrafiltered using a Centristat 20 kDa cut-off centrifugal filter
device (Satorius,Gottingen, Germany) to eliminate high
molecular weight compounds. The obtained filtrate was
desalted using a NAP5 gel filtration column (GE Healthcare Bio
Sciences, Uppsala, Sweden) to remove urea and electrolytes.
The sample was lyophilized in a Christ Speed-Vac RVC 2 18/
Alpha 1 2 (Christ, Osterode am Harz, Germany) and stored at
4°C until use. Finally, the samples were re-suspended in 200
µL HPLCgrade H2O and injected into CE-MS with 2 psi for 99
sec, resulting in injection volumes of 280 nL. Capillary
electrophoresis coupled to mass spectrometry (CE-MS)
analysis was performed as described using a P/ACE MDQ
capillary electrophoresis system (Beckman Coulter, Fullerton,
USA) on-line coupled to a MicroQTOF MS (Bruker) [39]. The
ESI sprayer (Agilent Technologies, Palo Alto, CA, USA) was
grounded, and the ion spray interface potential was set
between −4.0 and −4.5 kV. Data and MS acquisition methods
were automatically controlled by the CE via contact-close-
relays. Spectra were accumulated every 3 s, over a range of
m/z 350 to 3000. Details on accuracy, precision, selectivity,
sensitivity, reproducibility, and stability of the CE-MS method
have been provided previously [40,41]
Peptide sequencing
For sequencing, processed urine samples were also
separated on a Dionex Ultimate 3000 RSLS nano flow system
(Dionex, Camberly UK). A 5 ml sample was loaded onto a
Dionex 5 mm C18 nano trap column at a flow rate of 5 ml/min.
Elution was performed on an Acclaim PepMap 75 mm C18
Figure 5.  Macrophage infiltration (A) and collagen accumulation (B) in HFFD fed mice (■) compared to control fed mice
(▲).  Data are means ± SEM for 12 mice per group; *p=0.0217. Pictures for macrophage staining display representative areas of
kidneys from control or HFFD fed mice. Magnification x20. Pictures for collagen staining display representative tubulointerstitium of
kidneys from control or HFFD fed mice. Magnification x20.
doi: 10.1371/journal.pone.0076703.g005
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nano column over 100 min. The sample was ionised in positive
ion mode using a Proxeon nano spray ESI source (Thermo,
Fisher Hemel UK) and analysed in an Orbitrap Velos FTMS
(Thermo Finnigan, Bremen, Germany). The MS was operated
in data-dependent mode to switch between MS and MS/MS
acquisition and parent ions were fragmented by (high-) energy
collision-induced dissociation and also electron transfer
dissociation. Data files were searched against Mus musculus
entries in the Swiss-Prot database without any enzyme
specificity using Open Mass Spectrometry Search Algorithm
(OMSSA, http://pubchem.ncbi.nlm.nih.gov/omssa) with an e-
value cut-off of 0.1. No fixed modification and oxidation of
methionine as variable modifications were selected. Mass error
windows of 10 ppm for MS and 0.05 Da (HCD) or 0.5 Da (CID,
ETD) for MS/MS were allowed. For further validation of
obtained peptide identifications, the strict correlation between
peptide charge at pH 2 and CE-migration time was utilized to
minimize false-positive identification rates [42]. Calculated CE-
migration time of the sequence candidate based on its peptide
sequence (number of basic amino acids) was compared to the
experimental migration time. Peptides were accepted only if
they had a mass deviation below ± 80 ppm and a CE-migration
time deviations below ± 2 min.
Data processing
Mass spectral ion peaks representing identical molecules at
different charge states were deconvoluted into single masses
using MosaiquesVisu software [43]. Only those signals with z
>1 that were observed in a minimum of 2 consecutive spectra
with signal-to-noise ratios >4 were included. The software
employs a probabilistic clustering algorithm and uses both
isotopic distribution as well as conjugated masses for charge-
state determination of peptides/proteins. The resulting peak list
characterizes each polypeptide by its molecular mass, CE-
migration time, and ion signal intensity (amplitude) value. To
minimize effects of biological and analytical variability between
the different lots, a normalization of retention time, signal
intensity and mass was performed as described [44]. All
detected peptides were deposited, matched, and annotated in
a Microsoft SQL database, allowing further analysis and
comparison of multiple samples [45]. Peptides were considered
identical within different samples when mass deviation was
lower than 50 ppm for small peptides or 75 ppm for larger
peptides and proteins. Due to analyte diffusion, CE peak widths
increase with CE migration time. In the data clustering process
this effect was compensated by linearly increasing cluster
widths over the entire measurement from 2 to 5%.
Statistical analysis
All data are presented as means ± SEM. Statistical analysis
was performed using GraphPad software
(www.graphpad.com). Analysis of the two groups (control vs.
high fat fructose diet) was assessed by a two-tailed unpaired t-
test. Statistical significance was reached at a p-value below
0.05.
Figure 6.  Absence of mesangial matrix expansion in HFFD fed mice (■) compared to control fed mice (▲).  Mesangial matrix
expansion is evaluated by the ratio of the matrix surface to the total surface of the glomerulus after Periodic Acid Staining. Data are
means ± SEM for 12 mice per group; ns. Pictures display representative glomeruli of kidneys from control or HFFD fed mice.
Magnification x40.
doi: 10.1371/journal.pone.0076703.g006
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Results
HFFD diet induces metabolic syndrome and T2D in
mice
Five weeks old male C57BL/6 mice were separated into two
groups (n=36 mice/group). The control group received a
standard control diet and tap water. The other group (HFFD)
received a high fat diet (45% of fat) and 30% fructose in tap
water. In Table 1, we summarized the parameters to determine
instauration of metabolic syndrome in HFFD fed C57BL/6 mice.
The different parameters are ordered based on first
appearance of significance in time. Mice receiving HFFD
displayed a significantly higher energy intake starting at week
1. Body weight of the HFFD group was increased starting at
week 3 while the food intake in this group started to decrease.
After 4 weeks on HFFD, we observed that plasma triglycerides,
total cholesterol, and HDL were significantly elevated. The
difference observed for weight between HFFD and control mice
was confirmed by a significant gain of fat and lean mass in
HFFD mice at week 8. At the same time, the HFFD mice
started to be hyperglycemic compared with controls. At week
16, plasma LDL levels were significantly higher in the HFFD
mice. The figures 1 and 2 show the evolution of these
parameters throughout the eight months of study. No difference
was observed in the water intake. Histological analysis of the
liver performed at 8 months revealed a marked vacuolar
degeneration, indicating fat accumulation in the liver (Figure 3).
This observation is consistent with the development of non
alcoholic fatty liver (NAFLD) due to the excess of fructose
intake [46]. Collectively these data strongly suggest the
presence of metabolic syndrome as early as 4 weeks and of
associated type 2 diabetes (T2D) as early as 8 weeks after
initiation of a HFFD in C57BL/6 mice.
HFFD diet induces glomerular hyperfiltration and
microalbuminuria only in late stage metabolic
syndrome
Next we studied the effect of metabolic syndrome and T2D
on kidney function. The glomerular filtration rate (GFR) was
determined based on inulin clearance after 3, 6 and 8 months
Figure 7.  The measurement of glomerular capillary basement membrane thickness by electron microscopy showed a
tendency to increase in the HFFD group at 8 months (A).  HFFD fed mice (■) compared to control fed mice (▲) and data
represent means ± SEM for 12 mice per group; ns. The assessment of foot process effacement, expressed as the mean width of
the podocytes foot process (FPW), did not showed a significant difference between the HFFD fed mice (5) compared to control fed
mice (<) (B). Data represent means ± SEM for 12 mice per group; ns.
doi: 10.1371/journal.pone.0076703.g007
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of HFFD. GFR was not significantly different between the
control and the HFFD group at the early time points (3 and 6
months), but HFFD mice displayed low, but significant,
hyperfiltration after 8 months of diet (Figure 4A). This
hyperfiltration was accompanied by a 2-fold increase in
albuminuria (Figure 4B), but without change in the blood
pressure (Figure 4C). This assessment suggests late and mild
kidney dysfunction in metabolic syndrome in C57BL/6 mice.
HFFD induces only minor histological modifications in
the kidney
Since we only observed mild functional changes after 8
months of HFFD, we studied kidney histological modifications
at this time point. Macrophage infiltration was quantified by
immunohistological staining for F4/80 in the tubulointerstitium.
We observed a 2-fold increased F4/80 staining in kidneys of
HFFD mice compared to the control group (Figure 5A).
Tubulointerstitial collagen accumulation was also studied by
immunostaining for collagen III (Figure 5B). Eight months of
HFFD was without effect on tubulointerstitial collagen III
deposition. Moreover Periodic Acid staining did not show
mesangial matrix expansion (Figure 6). Glomerular basement
membrane (GBM) thickening and foot process effacement are
early events in diabetic nephropathy [47]. We studied the
thickness of the GBM and assessed the foot process
Table 1. Parameters to determine instauration of metabolic
syndrome in HFFD fed C57BL/6 mice.
 
Onset of
significance
Control
group
values
HFFD
group
values p-value
Test
frequency
Energy intake
(kcal) 1 week
456.2 ±
12.3
1398 ±
129.2
<
0.0001 weekly
Body weight
(grams) 3 weeks
24.88 ±
0.19
26.79 ±
0.23
<
0.0001 weekly
Food intake
(grams) 3 weeks
160.0 ±
8.17
96.33 ±
9.26 0.0004 weekly
Triglycerides
(mmol/L) 4 weeks
1.00 ±
0.07
1.45 ±
0.12 0.0023 monthly
Cholesterol
(mmol/L) 4 weeks
2.89 ±
0.09
3.46 ±
0.18 0.0083 monthly
HDL (mmol/L) 4 weeks 2.64 ±0.08
3.10 ±
0.16 0.0148 monthly
Fat mass (% of
body mass) 8 weeks
1.16 ±
0.11
4.55 ±
0.45
<
0.0001 monthly
Lean mass (% of
body mass) 8 weeks
20.26 ±
0.24
21.53 ±
0.22 0.0003 monthly
Glucose
(mmol/L) 8 weeks
14.77 ±
0.79
18.41 ±
1.21 0.0164 monthly
LDL (mmol/L) 16 weeks 0.14±0.01
0.20 ±
0.02 0.0071 monthly
The different parameters are ordered based on first appearance of significance in
time. The frequency of analysis for each parameter is displayed in the last column.
n=36 / group.
doi: 10.1371/journal.pone.0076703.t001
effacement using electron microscopy. This analysis showed a
non-significant difference (0.353±0.009 vs 0.375±0.0106 µM)
towards increased GBM thickness and no foot process
effacement in HFFD mice (Figure 7). These data suggest
absence of advanced diabetic nephropathy lesions but
inflammation of the kidney tissue after 8 months of HFFD.
Comparison of the HFFD mouse urinary peptidome
with the human urinary peptidome of T2D patients
suggests absence of T2Ddiabetic nephropathy
The results obtained so far suggest that 8 months of HFFD
was not associated with significant renal lesions in C57BL/6
mice. In previous studies in humans, analysis of the urinary
proteome allowed the identification of 273 peptides associated
to CKD [40]. These peptides were also significantly modified in
T2D patients with diabetic nephropathy [48] [49]. Similarly, we
have studied the HFFD-induced changes in the mouse urinary
peptidome. The analysis of the urinary peptidome of control
(n=10) and mice fed 8 months of HFFD (n=11) led to the
detection of a total of 2591 urinary peptides for control mice
and 2687 peptides for HFFD mice (Figure 8A, shown for HFFD
mice). When comparing the urinary peptide content of control
and HFFD mice we observed 62 peptides with different urinary
abundance (Figure 8B). To date, sequence analysis identified
30 peptides of these 62 (Table S1). Around 80% (24 out of 30)
of these peptides were found to be fragments of collagen with
27% being down-regulated and 53% up-regulated (Figure 9A).
For comparison with the human situation we next studied the
regulation of the 273 peptides associated to CKD in healthy
controls (n=33, data obtained from [40]), in patients with T2D
without diabetic nephropathy (albuminuria<30mg/L, n=75) and
in patients with T2D with diabetic nephropathy
(albuminuria>300mg/L, n=47) that were previously studied by
Molin [50]. In the T2D patients without diabetic nephropathy,
the peptidome profile was very similar to HFFD mice, with 29%
of collagen fragments down-regulated and 45% up-regulated
compared to healthy controls (Figure 9B). However, the
peptidome of HFFD mice was different from T2D patients with
diabetic nephropathy as in these patients, collagen fragments
were mostly down-regulated (47% down- and 27% up-
regulated, Figure 9B).
Discussion
The purpose of our study was to investigate renal lesions
after long term (8 months) of high fat high fructose diet-induced
metabolic syndrome in the highly used and studied C57BL/6
mouse strain. We confirmed that consumption of a 45% kcal fat
with 30% fructose water diet by wild type C57BL/6 led to the
rapid installation of metabolic syndrome (4 weeks) and T2D (8
weeks). We next studied in detail the renal phenotype and
compared our results to the specifications of the Diabetic
Complications Consortium (DiaComp; www.diacomp.org). The
DiaComp research criteria for validating a progressive mouse
model of diabetic nephropathy implies a decline greater than
50% in GFR over the lifetime of the animal, an increase greater
than 10 fold in albuminuria, advanced mesangial matrix
expansion, tubulointerstitial fibrosis and glomerular basement
Kidney Lesions in Metabolic Syndrome in Mice
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membrane thickening superior by 50% over baseline. During
our study, we observed that mice with metabolic syndrome
develop minimal renal injury exemplified by low level
albuminuria (2 fold higher than the control group) or mild
hyperfiltration (1.5 fold higher than the control group) after 8
months of HFFD. In addition, we observed neither mesangial
matrix expansion nor fibrosis or significant GBM thickening, but
only some minor podocyte effacement. Clearly these
characteristics are far from the DiaComp recommendations.
Analysis of human urine proteomic profile allows early
diagnosis of kidney diseases such as CKD [51] or diabetic
nephropathy [48] and increasingly, proteomics are involved in
the clinical diagnosis [52,53]. Here, we compared the urinary
peptide content of control mice to HFFD mice and identified 62
differentially excreted peptides. We obtained sequence
information for 30 of these 62 peptides and we compared those
to the human urinary peptide markers of diabetic nephropathy
[48]. In both human and mice, most of the urinary peptides
were collagen fragments suggesting similarities between the
human and C57BL/6 mouse urinary peptidome. Interestingly,
the observed “up and down” collagen peptide profile in HFFD
mice was very similar to that of T2D patients without diabetic
nephropathy but clearly different from that of T2D patients with
diabetic nephropathy. This result suggests absence of diabetic
nephropathy in HFFD mice, thereby confirming the functional
and histological observations. In addition, this inversion of the
direction regulation of urinary collagen fragments in diabetic
nephropathy in humans, i.e. a significant decrease in urinary
collagen fragments, is thought to be related to increased
collagen deposition in the diabetic kidney [54] and correlates to
the absence of tubulointerstitial fibrosis in mice receiving 8
months of HFFD. Overall, these data based on urinary
peptidome analysis further suggest that the HFFD diet does not
‘‘model’’ chronic kidney disease in T2D patients.
Five stages in the development of renal changes in human
diabetes have been described [55], but an official description of
staging of diabetic nephropathy in mice is not available. Based
on our results, 8 months of HFFD diet in C57BL/6 mice
Figure 8.  Comparison of the urinary peptidome content between control (n=10) and HFFD (n=11) at 8 months of age
mice.  (A) A contour plot representing the compiled urinary peptidome of all HFFD mice showing 2687 urinary peptides. Each blue
to white colored dot or peak represents a urinary peptide identified by a specific mass (kDa) and migration time on the CE (min).
When a peptide is detected but of low abundance it is represented by a blue dot. Increasing abundance of peptide is represented by
a change of color towards white. At the same time the abundance is given by the height of the peak. Therefore a dot equals low
abundance and a peak equals higher abundance, with the height of the peak being the relative abundance compared to the other
peptides. (B) Representation of the 62 peptides which differ in urinary abundance between control and HFFD fed mice. In panel B,
the scale was amplified 2-fold to improve the representation of the peptides.
doi: 10.1371/journal.pone.0076703.g008
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corresponds best to human stage 1 renal changes in diabetes
(hyperfiltration, absence of thickened GBM and slightly
elevated urinary albumin). Together with our other observations
of absence of diabetic nephropathy it is clear that the C57BL/6
strain is not the most adequate strain for studies of renal
lesions in HFFD induced T2D.
The influence of the genetic background on the disease
phenotype has been described in mice [56]. A number of
studies already described the impact of the mouse strain on the
responsiveness to treatment. C57BL/6 mice are for example
relatively resistant to STZ-induced type 1 diabetes compared to
DBA/2J and KK/H1J mice [57,58]. The genetic background can
also have significant impact on the responsiveness to a specific
diet. C57BL/6 mice fed with a high fat high carbohydrate diet
displayed increased body weight, had more overall fat, and
particularly increased adipose tissue in comparison with A/J
mice, although developing similar levels of hyperglycemia,
hyperinsulinemia, and hypercholesterolemia [59,60]. The
genetic background has also been reported to influence the
outcome of CKD or glomerulosclerosis. In reversible unilateral
ureteral obstruction [61], the development of CKD was
observed in C57BL/6 mice but not in BALB/c. On the contrary,
in a 5/6 nephrectomy model, C57BL/6 mice presented only
mild glomerulosclerosis in contrast to both 129/Sv and Swiss
mice [62]. Hence one of the possibilities to improve on the
development of kidney disease in HFFD is testing different
mouse strains. However deviation from the C57BL/6 strain
rules out the use of the wealth of genetically engineered mice
on this genetic background.
Our choice to use a high fat high fructose diet was driven by
its high similarity with the actual human western diet and by the
panel of symptoms it causes (eg hyperinsulinemia, insulin
resistance, impaired glucose tolerance, increase abdominal fat
deposition, hepatic steatosis and inflammation). The
hypothesis to study the renal complications in this established
model of metabolic syndrome was supported by impaired renal
function and the renal lesions observed in studies using high
fat or high fructose separately in rodents [23-26]. Surprisingly,
the combination of these two diets, although clearly inducing
metabolic syndrome, did not lead to the expected kidney
Figure 9.  Comparison of the regulation of urinary peptide fragments in the HFFD mouse model (a) with human with type
2 diabetes (T2D) with or without diabetic nephropathy (9B).  
doi: 10.1371/journal.pone.0076703.g009
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damage. A possible explanation of the absence of effect on
renal lesions of the HFFD is, when compared to a high fat diet
only [23], that the quantity of the daily ingested fat in our
experiments is lower (0.52 g of fat/day for HFFD vs 0.62g of
fat/day for high fat diet). The additional calories provided by the
fructose beverage are compensated by decrease in food intake
[63]. This minor daily difference in fat intake over a long period
(i.e. 8 months) potentially explains the observed difference in
renal lesions. Another possible explanation could be modified
water intake due to the presence of fructose. Indeed, as
described by Bouby et al. [64], glucose in drinking water can
increase water intake, slowing down the progression of renal
injury in rats. However, we observed that the high
concentration of fructose in the drinking water did not lead to a
higher water intake.
Thus the current challenge is to find the balance between
diets that lead quickly to advanced renal disease (but that do
not mimic the situation from human nutritional perspective) and
diets that need a longer time of exposure to induce the same
stage of disease (but imitating closely the human nutritional
input). An option to accelerate renal lesions in C57BL6 mice
could be to superimpose high fat high fructose diets to strains
predisposed to obesity such as the Lepob, Leprdb, KK.Cg-Ay
strain. Indeed, Zhang et al. [65] combined a strain predisposed
to obesity (db/db) and a high fat diet and showed that a high fat
diet exacerbates nephropathy and causes early renal failure.
However instauration of renal failure was fast (4 weeks) and
does not correspond to chronic disease observed in humans.
Once again, a balance needs to be found between models that
quickly lead to severe renal disease and models that allow
studies of development of chronic disease. Moreover, most of
the knockout animals are on the C57BL6 background. The use
of these genetic models of T2D could necessitate crossing
them with knockout animals in futures studies, but genetic T2D
model are associated with issues such as reduced fertility [66]
and many backcrosses (around 10) to reach a unique (99.9%)
new genetic background will be necessary. Increasing the
quantity of fat or fructose could be also considered to
accelerate the renal lesions but a review of existing literature
has highlighted their serious consequences. Using of a 60% fat
diet instead of the 45% on this study would quickly induced
obesity on a much shorter time but should be considered
extreme from a nutritional perspective. In the same way, some
studies use fructose concentrations up to 55%. If we assumed
that the fatty liver, a symptom of metabolic syndrome, is earlier
observed in these mice we cannot overshadow the increased
risk of severe NAFLD and hepatic necroinflammatory [67]
An ultimate option to accelerate renal lesions in C57BL/6
mice subjected to a HFFD is to remove one of the kidneys
before initiation of the diet. Indeed, it has been shown that
uninephrectomy leads to exacerbation of the lesions of diabetic
nephropathy in db/db obese mice [68]. In addition, chronic
ingestion of fructose worsens the decrease of renal function,
proteinuria, and glomerulosclerosis induced by subtotal
nephrectomy in the rat [23-26].
In conclusion, the present study demonstrates that the HFFD
is an efficient animal model of metabolic syndrome in C57BL/6
mice but suggests that the kidney is particularly resistant in this
strain because only very early signs of kidney damage are
observed. Potential solutions to exploit this model for advanced
renal lesions in C57BL/6 mice include prolongation of the diet,
which is feasible but clearly time consuming or, accelerate
disease progression by coupling a HFFD with unilateral
nephrectomy.
Supporting Information
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